Pre-Conference Workshop Day - Tuesday | July 9, 2024

9:00 am Analyzing RNP and Protein Delivery Models to Highlight Key Advantages & Drawbacks, & Pinpoint the Most Effective Delivery Method

  • Tian Zhu Chief Executive Officer & Co-Founder, GenEditBio
  • Dana Foss Chief Executive Officer & Co-Founder, Editpep

Synopsis

With a variety of delivery models currently being utilized in the in vivo cell engineering and gene editing space, and ongoing debates about the most effective approach, this workshop investigates which delivery system is most effective for your treatment, the impact of each delivery system on toxicity and features case studies from leading companies implementing these methods.

12:00 pm Lunch Break & Networking

1:00 pm Refining Preclinical Regulations: Clarifying Requirements for Safety, Efficacy, and Pharmacological Evidence to Establish the Regulatory Gold Standard & Minimize Uncertainty in Clinical Translation

  • Laura Green Director, Program Management, Umoja Biopharma
  • Eric Kmiec Founder, Chief Executive & Scientific Officer, CorriXR Therapeutics

Synopsis

As the in vivo cell engineering and gene editing space rapidly develops, leaving uncertainties in regulatory requirements, this workshop delves into considerations for effective model selection and strategies for producing comprehensive safety and efficacy evidence to effectively prepare for treatment evaluation and approval from regulatory boards.